{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 7.8947372, "regularMarketPrice": 1.64, "exchange": "NCM", "shortName": "SELLAS Life Sciences Group, Inc", "longName": "SELLAS Life Sciences Group, Inc.", "messageBoardId": "finmb_262231850", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "firstTradeDateMilliseconds": 1205328600000, "priceHint": 4, "preMarketChange": 0.100000024, "preMarketChangePercent": 6.0975623, "preMarketTime": 1684225169, "earningsTimestampEnd": 1692014400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.04, "epsForward": -0.88, "epsCurrentYear": -0.68, "priceEpsCurrentYear": -2.4117646, "sharesOutstanding": 28347900, "bookValue": 0.231, "fiftyDayAverage": 1.4698, "fiftyDayAverageChange": 0.17019999, "fiftyDayAverageChangePercent": 0.11579806, "twoHundredDayAverage": 2.52965, "twoHundredDayAverageChange": -0.88965, "twoHundredDayAverageChangePercent": -0.35168898, "marketCap": 53219476, "forwardPE": -1.8636364, "priceToBook": 7.099567, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "preMarketPrice": 1.74, "regularMarketChange": 0.120000005, "regularMarketTime": 1684180800, "regularMarketDayHigh": 1.64, "regularMarketDayRange": "1.51 - 1.64", "regularMarketDayLow": 1.51, "regularMarketVolume": 137579, "regularMarketPreviousClose": 1.52, "bid": 0.0, "ask": 0.0, "bidSize": 11, "askSize": 10, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 1.51, "averageDailyVolume3Month": 486195, "averageDailyVolume10Day": 222660, "fiftyTwoWeekLowChange": 0.47000003, "fiftyTwoWeekLowChangePercent": 0.40170944, "fiftyTwoWeekRange": "1.17 - 5.58", "fiftyTwoWeekHighChange": -3.94, "fiftyTwoWeekHighChangePercent": -0.7060932, "fiftyTwoWeekLow": 1.17, "fiftyTwoWeekHigh": 5.58, "dividendDate": 1573171200, "earningsTimestamp": 1683835927, "earningsTimestampStart": 1691578740, "displayName": "SELLAS Life Sciences", "symbol": "SLS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Times Square Tower", "address2": "Suite 2503 7 Times Square", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "646 200 5278", "website": "https://www.sellaslifesciences.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Dr. Angelos M. Stergiou M.D., ScD h.c.", "age": 46, "title": "Founder, Pres, CEO & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 921985, "fmt": "921.99k", "longFmt": "921,985"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Barbara A. Wood Esq.", "age": 59, "title": "Exec. VP, Gen. Counsel & Corp. Sec.", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 632660, "fmt": "632.66k", "longFmt": "632,660"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 8078, "fmt": "8.08k", "longFmt": "8,078"}}, {"maxAge": 1, "name": "Mr. Robert M. Francomano", "age": 55, "title": "Sr. VP & Chief Commercial Officer", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 667354, "fmt": "667.35k", "longFmt": "667,354"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John Thomas Burns CPA", "age": 37, "title": "Sr. VP & CFO", "yearBorn": 1985, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dragan  Cicic M.D., MBA", "age": 59, "title": "Sr. VP of Clinical Devel.", "yearBorn": 1963, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andrew  Elnatan", "title": "VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}